mobocertinib

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	3.456		High	0.89
caco2-efflux	Caco-2 efflux ratio (BA/AB)	6.950		High	0.89
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	9.290	10^-6 cm/s	High	0.89
dh-clint	Dog hepatocyte intrinsic clearance	7.889	uL/min/10^6 cells	High	0.89
dppb	Dog plasma protein binding (% unbound)	1.140	%	High	0.89
fcs-ppb	Fetal calf serum protein binding (% unbound)	5.810	%	High	0.89
herg	hERG pIC50	5.378	pIC50	High	0.89
hh-clint	Human hepatocyte intrinsic clearance	9.078	uL/min/10^6 cells	High	0.89
hlm-clint	Human liver microsomal intrinsic clearance	48.417	uL/min/mg protein	High	0.89
hppb	Human plasma protein binding (% unbound)	1.190	%	High	0.89
kinase-safety-class	AAK1,ACVR2B,ALK,AURKA,AXL,BLK,BMX,BTK,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK4,CLK4,CSF1R,DDR1,EGFR,EIF2AK3,EPHA2,ERBB2,ERBB4,FGFR1,FLT3,GAK,GRK2,IGF1R,INSR,INSRR,IRAK1,IRAK3,IRAK4,ITK,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP3K1,MAP3K11,MAP3K14,MAP3K21,MAP3K9,MAP4K1,MAP4K3,MAP4K5,MAPK10,MAPK7,MARK4,MELK,MET,MKNK2,NTRK1,PDGFRB,PDK1,PDK2,PDK4,PLK1,PLK2,PLK3,PLK4,PRKCD,PTK6,RET,RIPK3,SIK2,SIK3,SRC,STK33,SYK,TEK,TNK1,TTK,ULK1,YES1	75
kinase-selectivity-class	AAK1,ALK,BLK,BMX,BTK,CAMK2A,CAMK2D,CSF1R,EGFR,ERBB2,ERBB4,FLT3,GAK,IGF1R,INSR,IRAK3,JAK3,LRRK2,MAP3K9,MAPK7,PDK4,PLK2,STK33,TNK1	24
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	2.958		High	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	12.417		High	0.89
mh-clint	Mouse hepatocyte intrinsic clearance	44.978		High	0.89
mppb	Mouse plasma protein binding (% unbound)	0.940		High	0.89
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	36.141		High	0.89
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	3.770	%	High	0.89
rat-kpuu-brain	Rat brain Kpuu	0.029	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	25.942	uL/min/10^6 cells	High	0.89
rh-fuinc	Rat hepatocyte fraction unbound in incubation	3.530	%	High	0.89
rppb	Rat plasma protein binding (% unbound)	1.020	%	High	0.89
solubility-dd	Solubility at pH 7.4 in DMSO	92.257	uM	High	0.89

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	173.71	43.03	114	901	939076	89688356
Metastases to central nervous system	54.72	43.03	16	999	17526	90609906
Dry skin	47.51	43.03	22	993	88051	90539381

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	200.39	38.66	138	1193	1139367	109448601
Metastases to central nervous system	66.18	38.66	20	1311	22797	110565171
Dry skin	47.55	38.66	24	1307	107629	110480339
Non-small cell lung cancer	46.15	38.66	12	1319	7923	110580045
Rash	39.93	38.66	49	1282	820915	109767053
Death	39.39	38.66	45	1286	698824	109889144

Source	Code	Description
ATC	L01EB10	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
FDA MoA	N0000020010	HER1 Antagonists
MeSH PA	D000092004	Tyrosine Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
FDA MoA	N0000190118	Cytochrome P450 3A Inducers
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:231911	renoprotective agent

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 40MG BASE	EXKIVITY	TAKEDA PHARMS USA	N215310	Sept. 15, 2021	DISCN	CAPSULE	ORAL	Sept. 15, 2026	NEW CHEMICAL ENTITY
EQ 40MG BASE	EXKIVITY	TAKEDA PHARMS USA	N215310	Sept. 15, 2021	DISCN	CAPSULE	ORAL	Sept. 15, 2028	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 INSERTION MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

mobocertinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	INHIBITOR	Kd	6.67	DRUG LABEL	DRUG LABEL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	INHIBITOR	IC50	9.40	DRUG LABEL	DRUG LABEL
Tyrosine-protein kinase BTK	Kinase	Q06187	BTK_HUMAN	INHIBITOR	IC50	8.55	DRUG LABEL
Tyrosine-protein kinase JAK3	Kinase	P52333	JAK3_HUMAN	INHIBITOR	IC50	8.66	DRUG LABEL
Tyrosine-protein kinase Blk	Kinase	P51451	BLK_HUMAN	INHIBITOR	IC50	9.70	DRUG LABEL
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN	INHIBITOR	IC50	8.64	DRUG LABEL
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN	INHIBITOR	IC50	10	DRUG LABEL

ID	Source
39HBQ4A67L	UNII
2389149-74-8	SECONDARY_CAS_RN
C5418176	UMLSCUI
CHEBI:758219	CHEBI
CHEMBL4650319	ChEMBL_ID
118607832	PUBCHEM_CID
DB16390	DRUGBANK_ID
CHEMBL4802239	ChEMBL_ID
D12001	KEGG_DRUG
11183	INN_ID
C000720862	MESH_SUPPLEMENTAL_RECORD_UI
10468	IUPHAR_LIGAND_ID
40609711000001106	SNOMEDCT_US
40618011000001101	SNOMEDCT_US
4040829	VANDF
350405	MMSL
39900	MMSL
d09808	MMSL
018847	NDDF
018848	NDDF
2570736	RXNORM
39HBQ4A67L	INXIGHT DRUGS